University of Alberta cancer drug secures funding for human trials

Jay Rosove Video Journalist - 7 May 2020

A possible new cancer treatment developed at the University of Alberta is expected to be heading to human trials at three Canadian cancer centres, before year's end. John Mackey (FOMD) is interviewed.

The new phase in the drug's development would be made possible thanks to $5 million in funding from Edmonton-based investors.

The drug, known as PCLX-001, comes in pill form and is designed to fight blood cancers like leukemia and lymphoma.

Tests have shown the drug kills proteins in cancer cells, keeping them from multiplying, so those harmful cells die.

"We have a reason to think this is going to be much more toxic to cancer cells," Cross Cancer Institute Director of Clinical Trials, Dr. John Mackey told CTV News Edmonton via video chat.

Read More......